NASDAQ:RCM - R1 RCM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $28.57
  • Forecasted Upside: 37.23 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.2 (0.97%)

This chart shows the closing price for RCM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New R1 RCM Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RCM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RCM

Analyst Price Target is $28.57
▲ +37.23% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for R1 RCM in the last 3 months. The average price target is $28.57, with a high forecast of $35.00 and a low forecast of $22.00. The average price target represents a 37.23% upside from the last price of $20.82.

This chart shows the closing price for RCM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in R1 RCM. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/22/2021Bank of AmericaInitiated CoverageBuy$27.00Low
6/2/2021Robert W. BairdInitiated CoverageOutperform$30.00Medium
5/27/2021SVB LeerinkReiterated RatingBuyHigh
2/16/2021KeyCorpBoost Price Target$27.00 ➝ $35.00Low
2/9/2021CowenBoost Price TargetOutperform$22.00 ➝ $33.00Low
1/6/2021KeyCorpBoost Price TargetOverweight$24.00 ➝ $26.00N/A
12/9/2020Royal Bank of CanadaBoost Price TargetOutperform$20.00 ➝ $27.00Low
12/3/2020SVB LeerinkBoost Price TargetOutperform$22.00 ➝ $26.00Medium
11/4/2020Cantor FitzgeraldBoost Price TargetOverweight$18.00 ➝ $22.00Medium
11/4/2020SVB LeerinkBoost Price TargetOutperform$18.00 ➝ $22.00Medium
11/2/2020KeyCorpBoost Price TargetOverweight$17.00 ➝ $24.00High
8/5/2020SVB LeerinkUpgradeMarket Perform ➝ Outperform$14.00 ➝ $18.00Medium
7/14/2020KeyCorpBoost Price TargetOverweight$12.00 ➝ $15.00Medium
4/20/2020Royal Bank of CanadaInitiated CoverageOutperform$12.00High
4/13/2020SVB LeerinkInitiated CoverageMarket Perform$10.00Medium
1/21/2020Cantor FitzgeraldReiterated RatingOverweight$15.00 ➝ $17.00High
1/14/2020KeyCorpBoost Price TargetOverweight$14.00 ➝ $15.00Low
1/10/2020Dougherty & CoInitiated CoverageBuy$15.00Medium
9/12/2019Robert W. BairdSet Price TargetBuy$14.00Low
4/12/2019Cantor FitzgeraldBoost Price TargetOverweight$11.00 ➝ $13.00Medium
1/22/2019KeyCorpInitiated CoverageOverweight ➝ Overweight$10.00High
12/10/2018CitigroupInitiated CoverageBuy ➝ Buy$20.00Medium
9/4/2018Chardan CapitalInitiated CoverageBuy ➝ Buy$17.00High
8/10/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$10.00 ➝ $11.00Low
7/27/2018Cantor FitzgeraldReiterated RatingBuy$10.00Low
4/9/2018Robert W. BairdUpgradeNeutral ➝ Outperform$9.00Medium
3/13/2018Cantor FitzgeraldInitiated CoverageOverweight$9.00Medium
3/12/2018CowenReiterated RatingOutperform ➝ In-Line$5.00 ➝ $10.00Medium
2/26/2018Robert W. BairdReiterated RatingHold$7.00High
9/26/2017Robert W. BairdReiterated RatingHold$5.00High
8/24/2017Robert W. BairdReiterated RatingHold$5.00Low
(Data available from 7/25/2016 forward)
R1 RCM logo
R1 RCM, Inc. engages in the provision of revenue cycle management to healthcare providers. It offers end-to-end, modular revenue cycle, and physician advisory services. The company was founded by Mary Ann Tolan and J. Michael Cline in July 2003 and is headquartered in Chicago, IL.
Read More

Today's Range

Now: $20.82
Low: $20.36
High: $20.87

50 Day Range

MA: $22.36
Low: $19.88
High: $25.41

52 Week Range

Now: $20.82
Low: $13.21
High: $31.28


445,973 shs

Average Volume

1,009,934 shs

Market Capitalization

$5.45 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of R1 RCM?

The following sell-side analysts have issued stock ratings on R1 RCM in the last twelve months: Bank of America Co., Cantor Fitzgerald, Cowen Inc, KeyCorp, Robert W. Baird, Royal Bank of Canada, SVB Leerink LLC, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for RCM.

What is the current price target for R1 RCM?

7 Wall Street analysts have set twelve-month price targets for R1 RCM in the last year. Their average twelve-month price target is $28.57, suggesting a possible upside of 37.2%. KeyCorp has the highest price target set, predicting RCM will reach $35.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $22.00 for R1 RCM in the next year.
View the latest price targets for RCM.

What is the current consensus analyst rating for R1 RCM?

R1 RCM currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RCM will outperform the market and that investors should add to their positions of R1 RCM.
View the latest ratings for RCM.

What other companies compete with R1 RCM?

How do I contact R1 RCM's investor relations team?

R1 RCM's physical mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The healthcare provider's listed phone number is (312) 324-7820 and its investor relations email address is [email protected] The official website for R1 RCM is